This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis (IONS) Beats Earnings & Misses Revenues in Q1
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings beating estimates while revenues missing the same.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher
by Zacks Equity Research
Shares of Ionis Pharmaceuticals (IONS) rose 5.8% on Friday.
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
by Zacks Equity Research
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Alnylam Falls on Pfizer's Rare Disease Drug Success
by Zacks Equity Research
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer
by Zacks Equity Research
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
Ionis (IONS) Beats Both Earnings & Revenues in Q4
by Zacks Equity Research
Ionis Pharmaceutical (IONS) reported positive quarter with earnings and revenues beating estimates.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.
Biogen Halts Tysabri Development in Stroke as Study Fails
by Zacks Equity Research
Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.
Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options
by Zacks Equity Research
Surging implied volatility makes Ionis Pharmaceuticals (IONS) stock lucrative to the option traders.
Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies
by Zacks Equity Research
Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.
Ionis (IONS) Beats on Q3 Earnings, Revenues Miss
by Indrajit Bandyopadhyay
Ionis Pharmaceutical (IONS) reported mixed quarter with earnings beating estimates while revenues missing it.
Should You Buy Ionis (IONS) Ahead of Earnings?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.
4 Scorching Hot Momentum Stocks to Beat the Market
by Zacks Equity Research
This screen will help you to get into momentum stocks that are storming ahead. Highlighted stocks include: IONS, OSB and SKX.
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
by Zacks Equity Research
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
by Zacks Equity Research
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.
Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings
by Zacks Equity Research
Ionis Pharmaceuticals' (IONS) reported loss of 9 cents including stock based compensation was wider than expectation. However, sales beat estimates.
Why Earnings Season Could Be Great for Ionis (IONS)
by Zacks Equity Research
Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.
Ironwood (IRWD) Reports Positive Data on Reflux Candidate
by Zacks Equity Research
Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.
Why is Alnylam's (ALNY) Stock Close to 100% this Year?
by Zacks Equity Research
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.